Interventions are actions taken by or for individuals to reduce the risk, duration, or severity of adverse health conditions. Interventions may be population-based or personal.
DCP2 and GBD present what we know about which health interventions work for a comprehensive range of diseases, injuries, and disabilities in many different contexts. A large share of the disease burden in low- and middle-income countries is attributable to diseases and conditions for which cost-effective interventions are already known and feasible. Selecting the right intervention for a given disease and context matters a great deal. The tools on this page are designed to aid the task.
DCP2 and GBD demonstrate how decision makers could use cost-effectiveness information in combination with information on disease prevalence and avertable illness to determine which interventions should be extended and which ones should be questioned. If developing countries scale up interventions and extend health care services that are cost-effective, the impact on the disease burden could be substantial.
Download Results (CSV)
|
Download Full Data Set (XLS)
| Condition |
Intervention
|
Intervention type
|
Intervention description |
Intervention setting
|
Objective
|
Target population
|
Cost effectiveness
(US$/DALY)
|
Cost effectiveness estimate
(US$)
|
Cost effectiveness range
(US$/DALY)
|
Number of DALYs averted
(hundreds)
|
Number of deaths averted
(hundreds)
|
Quality of cost-effectiveness analysis evidence
|
|
Congestive heart failure
|
ACE inhibitor and beta-blocker, with diuretics |
Personal |
Use of ACE inhibitor and an optional beta-blocker (metoprolol), incremental to diuretics |
Local or district hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
150 |
- |
27-274 |
11.59 |
-- |
5 |
|
Myocardial infarction
|
Aspirin and beta-blocker |
Personal |
Aspirin with or without betablocker (atenolol) |
Local or district hospital, Referral hospital
|
acute management
|
Adults, Women of childbearing age, Adolescents and adults
|
14 |
- |
13-15 |
1.04 |
-- |
5 |
|
Myocardial infarction and stroke
|
Polypill |
Personal |
Combination treatment with aspirin, beta-blocker, thiazide diuretic, ACE inhibitor and statin, based on 10-year risk of cardiovascular disease |
Local or district hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
409 |
- |
-- |
-- |
-- |
5 |
|
Myocardial infarction
|
Streptokinase, with aspirin and beta-blocker |
Personal |
Incremental use of streptokinase, in addition to aspirin and beta-blocker (atenolol) |
Local or district hospital, Referral hospital
|
acute management
|
Adults, Women of childbearing age, Adolescents and adults
|
671 |
- |
-- |
1.04 |
-- |
5 |
|
Myocardial infarction
|
Tissue plasminogen activator, with aspirin and beta-blocker |
Personal |
Incremental use of tissue plasminogen activator in addition to aspirin and beta-blocker (atenolol) |
Local or district hospital
|
acute management
|
Adults, Women of childbearing age, Adolescents and adults
|
15,869 |
- |
-- |
0.42 |
-- |
5 |
Download Results (CSV)
|
Download Full Data Set (XLS)